Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dornier MedTech Epos Ultra

This article was originally published in The Gray Sheet

Executive Summary

Australian study of 160 plantar fasciitis patients treated with the extracorporaeal shockwave therapy (ESWT) device finds "no evidence to support a beneficial effect on pain, function and quality of life" compared with placebo at six and 12 weeks. Published in the Sept. 18 Journal of the American Medical Association and conducted by Rachelle Buchbinder, Cabrini Hospital, Victoria, Australia, et al., the study included patients randomized to receive either 1,000 mJ/mm or a placebo dose of 6.0 mJ/mm through three weekly treatments. Both groups showed "significant" improvements in pain and ability, investigators noted. The indication was approved via PMA in January (1"The Gray Sheet" Feb. 4, 2002, p. 25)...

You may also be interested in...



Dornier Ultrasound Device Enters U.S. Market To Treat Foot Swelling

Clinical trials will begin in February to support a supplemental PMA filing for Dornier MedTech's Epos Ultra extracorporeal shockwave therapy (ESWT) device to treat tendon inflammation

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 9)

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this ninth installment of a 10-part series, the experts talk about the importance of maintaining a record of the inspection.

Civica Rx Gets $55m Investment

Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.

UsernamePublicRestriction

Register

MT017175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel